Pharmaceutical Company Says Its New Anti-Depressant Is 'Worthless And Dumb'

Top Headlines

Recent News

How To Reform The Nation’s Prison System

With pressing issues such as overcrowding, overuse of solitary confinement, and the long-term incarceration of nonviolent offenders, many critics of the nation’s prison system are calling for sweeping reforms. Here are some of the proposals to improve the prison system:

Sight Of 400 War Elephants On Horizon Marks Hillary Clinton’s Arrival In Swing State

WHEELING, OH—Feeling the earth shake beneath them as they watched the procession climb over the foothills of the Appalachian Mountains toward their village, sources along the Ohio border confirmed Thursday that the sight of 400 war elephants marching on the horizon marked Democratic presidential candidate Hillary Clinton’s arrival to the critical swing state.

WNBA MVP Devastated After Roommate Moves Out Without Any Warning

CHICAGO—Saying she is now desperately searching for any options that will prevent her from being evicted, Chicago Sky forward and 2015 WNBA MVP Elena Delle Donne was reportedly left scrambling Thursday after her roommate moved out of their apartment without any warning whatsoever.

Impressive New Hire Figures Out Bare Minimum Of Work Job Requires On First Day

MILWAUKEE—Marveling at his extraordinary ability to learn the ropes at the technology firm and quickly fit right in with the rest of his colleagues, sources at Starpoint Solutions confirmed Thursday that impressive new hire Eric Myers has already figured out the bare minimum of work his job requires on the very first day.
End Of Section
  • More News
TV Listings
Just Like Everything Else!: Fox 8 p.m. EDT/7 p.m. ABC Pete's wife is still on him about building that darn shed, these kids are going to be the death of Sheila and Dave, and the hot next-door neighbor is up in EVERYBODY'S business! Sunday nights on ABC couldn't be any more familiar!

Special Coverage

Real Estate


Pharmaceutical Company Says Its New Anti-Depressant Is 'Worthless And Dumb'

EAST BRUNSWICK, NJ—At a press conference Monday, Peter Cafazzo, CEO of Brunley-Hunt Pharmaceuticals (BHP), introduced his company's latest anti-depressant, Cyntrex, a product he described as "a totally stupid waste of time that probably nobody will ever want ever."

Peter Cafazzo, CEO of Brunley-Hunt Pharmaceuticals, unveils Cyntrex, a "worthless new drug" that he says will make the company "the total laughingstock of the industry."

Though from the outset, BHP had hoped the new medication would revolutionize the treatment of depression, Cafazzo is less than enthusiastic about its chances against such industry leaders as Prozac and Zoloft.

"Cyntrex? Yeah, right. More like, Stupidtrex," a visibly downcast Cafazzo told reporters. "More like, Another-Awful-Product-That-Will-Probably-Make-Us-All-Bankruptrex. More like, I suck."

The new drug, which stimulates the production of neurotransmitters in sync with the body's natural diurnal catecholamine rhythms—causing a more even mood level than the frequent "crest and trough" patterns associated with traditional psychoactive medicinal treatments—is something that "everybody will laugh at," Cafazzo said.

Among the reasons Cafazzo cited for Cyntrex's "totally doomed future" is BHP's inability to do anything half as well as its chief competitors.

"Prozac is so great," Cafazzo said. "We'll never make anybody as happy as Prozac does. I just know it."

Added Cafazzo: "My life is shit."

The release of Cyntrex is the latest bold move by BHP, which has increased its share of the mental-health drug market from 7 to 11 percent during the five years Cafazzo has been the company's CEO, causing many to view BHP as the rising giant in $150 billion pharmaceutical industry.

Cafazzo, however, questions the validity of such an appraisal. "Eleven percent? Oh, I'm sure. Like a company's really going to do that well with such a total fucking loser asshole for a boss."

"Maybe I'll get a raise," he said. "Then I can use the money to buy a gun to blow my head off."

According to reports, top BHP researchers began having doubts about the drug during the early development stages, when they realized they couldn't do anything right ever ever ever, and that none of the pharmaceutical-industry leaders cared whether they lived or died. But work on the project continued, despite BHP's growing conviction that Cyntrex would be the worst product in pharmaceutical history.

"We should have just stopped trying back then during the development stage," BHP lab assistant Peter Ayers said. "But, no, we had to go and make ourselves look like idiots in front of the whole world. Us and our lousy little pills both. Why?"

Ayers then began beating his fists into the sides of his head while staring at the floor, repeating, "Why? Why, why, why, why, why?" before being restrained by loved ones.

Fellow BHP researcher Harlan Downing said that, in addition to treating depression, Cyntrex may have numerous other uses. "There is a strong possibility," Downing said, "that the particular disinhibitors activated by Cyntrex may be of great benefit in the treatment of Alzheimer's Disease." He then admitted that the drug will not be ready for such use for some time, repeatedly hitting his forehead into a wall and gently mumbling under his breath.

BHP's chief rival in the mood-altering drug field is Stafford Labs, manufacturer of Prozac. Stafford CEO Margaret Curry expressed faith that Prozac would maintain its position despite the new competition.

"We will emerge triumphant, for I am Margaret Curry, president of Stafford Labs!" she said. "My power is as of 50 CEOs! My marketing savvy is as of a legion of PR firms! My tricyclic monoinhibitor is a boon unto the people and a beacon unto the nations! My new promotional campaign to enhance brand awareness and increase market saturation of Prozac shall be cloaked in radiant beams of persuasive glory!"